Compare SMJF & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMJF | KLRS |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7M | 44.5M |
| IPO Year | 2025 | 2020 |
| Metric | SMJF | KLRS |
|---|---|---|
| Price | $1.21 | $1.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.33 |
| AVG Volume (30 Days) | 74.1K | ★ 76.9K |
| Earning Date | 12-01-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $68.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $1.33 |
| 52 Week High | $11.48 | $11.88 |
| Indicator | SMJF | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 27.45 |
| Support Level | $0.91 | N/A |
| Resistance Level | $3.72 | $2.66 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 5.16 | 2.26 |
SMJ International Holdings Inc specializes in the sale and distribution of a wide range of flooring products such as carpet tiles, polypropylene tiles, broadloom carpets, and vinyl tiles. It operates under the proprietary brand 'SMJ'. The company also supplies environmentally friendly flooring products, promoting sustainable building practices in Asia. Geographically, it has a presence across Malaysia, Indonesia, the Philippines, Vietnam, India, Singapore, and other markets. The company generates revenue mainly through the sale and distribution of its flooring products, prominently in Singapore.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.